Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CCR5 | P51681 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658843 | 0.87 | KDM4E (0.61) | KDM4EALDH1A1MAPTCCR5MCHR1 | |
| SCHEMBL19652140 | 0.85 | DRD2 (0.54) | KDM4EALDH1A1CCR5SIGMAR1MEN1 | |
| SCHEMBL19652261 | 0.84 | CCR5 (0.55) | KDM4EALDH1A1MAPTCCR5SIGMAR1 | |
| SCHEMBL28801570 | 0.78 | SIGMAR1 (0.70) | KDM4EALDH1A1MAPTSIGMAR1POLB | |
| SCHEMBL22674304 | 0.77 | SIGMAR1 (0.65) | KDM4EALDH1A1MAPTSIGMAR1POLB | |
| SCHEMBL16432718 | 0.77 | CD74 (0.50) | KDM4EALDH1A1MAPTCCR5MCHR1 | |
| SCHEMBL17828658 | 0.77 | KDM4E (0.50) | KDM4EALDH1A1MAPTCCR5MCHR1 | |
| SCHEMBL29321604 | 0.76 | SIGMAR1 (0.57) | CCR5SIGMAR1DRD2 | |
| SCHEMBL20665217 | 0.76 | ALDH1A1 (0.74) | KDM4EALDH1A1MAPTSIGMAR1MEN1 | |
| SCHEMBL29321598 | 0.76 | SIGMAR1 (0.57) | CCR5SIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | KDM4E 320/4885ALDH1A1 1563/4885MAPT 1414/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | KDM4E 320/4885ALDH1A1 1563/4885MAPT 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.